AstraZeneca slumps on drug trial setback and holds back the FTSE 100, Computacenter soars and Capita quantifies impact of underperforming contract

AstraZeneca slumps on drug trial setback and holds back the FTSE 100, Computacenter soars and Capita quantifies impact of underperforming contract
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Please sign in

If you are a registered user on Headlinemoney, please sign in